Dr. Richard Goldberg


Richard Goldberg

Richard M Goldberg, MD, served as West Virginia University Cancer Institute’s (WVUCI) Director, and Director of the WVU Cancer Signature Program from 2016 to 2019. He served as a member of WVU health sciences Vice President and Executive Dean, Clay Marsh’s leadership team. As WVUCI’s Director, he oversaw the clinical, research, and teaching missions of the cancer institute and its component organizations that include satellite clinical and clinical research locations that are dispersed throughout West Virginia.

Considered an international leader in gastrointestinal cancer treatment and research as well as in leadership of cancer programs in academic medicine, Dr. Goldberg has been principal investigator, co-PI, co-investigator and mentor on multiple research and training grants funded through the National Cancer Institute (NCI). He has published more than 360 papers in peer-reviewed journals. His clinical interests are in management of patients with malignancies originating in the gastrointestinal tract, particularly colorectal and neuroendocrine cancers. His research focused on defining new treatments, elucidating inherited cancer susceptibility, and identification of predictive and prognostic factors in GI cancers, with a focus on colorectal cancer. He ran the trial known as N9741 that led to the licensing of oxaliplatin in the US for the treatment of colorectal cancer. He also served as the Chairman of the Gastrointestinal Cancer Committee of both the North Central Cancer Treatment Group (NCCTG) and the Cancer and Acute Leukemia B (CALGB) which merged to form the Alliance for Clinical Trials in Oncology. Currently, he serves as the Associate Group Chair of this NCI funded clinical trials organization that is a member of the National Clinical Trials Network. The Alliance conducts clinical trials and does translational research across the US and Canada.

He is a sought after lecturer at academic centers and scientific conferences across the nation and the world. He has mentored many MD, MD/Ph.D., and Ph.D. doctoral students, post-doctoral researchers and junior faculty over his 33 years as a medical oncologist in academic settings.

He is a graduate of Harvard University, earning an undergraduate degree cum laude in biology in 1975 and received his medical degree from the State University of New York Upstate Medical University in 1979 where he was elected to the Alpha Omega Alpha honor medical society.

Prior to his arrival at WVU in 2017, he served as physician in chief of both the James Cancer Hospital at The Ohio State University (OSU) and, prior to that of the North Carolina Cancer Hospital, at the University of North Carolina in Chapel Hill (UNC). He was an Associate Director at both the OSU and the UNC Comprehensive Cancer
Centers and the Division Chief of Hematology and Oncology at UNC and Acting
Division Director of Medical Oncology at OSU. Prior to that, he was a consultant at the Mayo Clinic in Rochester and Associate Chair of the Department of Medicine at the Geisinger Clinic in Danville, PA.

Dr. Goldberg serves on several national scientific advisory committees and on the scientific advisory committee for a number of pharmaceutical companies at the corporate level. He is a Fellow in the American College of Physicians and the American Society of Clinical Oncology. He is married to Lynda Goldberg MBA, MPH and has two adult children.